Motherisk update: Safety of colchicine therapy during pregnancy

Michael Ong, Ran D. Goldman, Gideon Koren

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Question. A 27-year old patient in our clinic with familial Mediterranean fever (FMF) has been treated with colchicine for the last decade. She is planning her first pregnancy. What recommendations should we give her regarding use of cholchicine before and during pregnancy, bearing in mind that discontinuation of colchicine could lead ot complications from amyloidosis? Answer. Colchicine passes through the placenta in humans, is teratogenic in animals, and raises rates of male and female infertility. Based on several patients with chromosomal anomalies, some authorities recommend that patients who require colchicine therapy during pregnancy undergo amniocentesis with karyotyping. In contrast, an increasing body of evidence suggests that colchicine use throughout pregnancy carries no substantial teratogenic or mutagenic risk when used at recommended doses. Its use prevents febrile attacks of FMF and reduces the frequency of renal complications.

Original languageEnglish
Pages (from-to)967-969
Number of pages3
JournalCanadian Family Physician
Volume49
Issue numberAUG.
StatePublished - 1 Aug 2003
Externally publishedYes

Fingerprint

Dive into the research topics of 'Motherisk update: Safety of colchicine therapy during pregnancy'. Together they form a unique fingerprint.

Cite this